Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Premature Ejaculation Next Big Sexual Health Market Expected to Surpass ED
August 08, 2014 --
LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives.
According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market. In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.
"Promescent may seem like a miracle, but it is actually just great science," says Abraham. "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation. This means men are not deprived of sensation and neither are their partners."
Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:
Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.
"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham. "This helps men better satisfy their partners and gain sexual confidence."
Promescent is available on-line and over-the-counter at independent pharmacies across the nation. It is safe, effective, and doctor recommended.
For more information, please visit http://www.promescent.com/.
To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.
SOURCE Absorption Pharmaceuticals
Copyright 2014 PR Newswire. All Rights Reserved